Larimar Therapeutics Inc (LRMR) concluded trading on Thursday at a closing price of $2.91, with 3.6 million shares of worth about $10.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -56.95% during that period and on June 12, 2025 the price saw a loss of about -6.13%. Currently the company’s common shares owned by public are about 64.03M shares, out of which, 36.46M shares are available for trading.
Stock saw a price change of 18.29% in past 5 days and over the past one month there was a price change of 55.20%. Year-to-date (YTD), LRMR shares are showing a performance of -24.81% which decreased to -69.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.61 but also hit the highest price of $11.20 during that period. The average intraday trading volume for Larimar Therapeutics Inc shares is 1.18 million. The stock is currently trading 27.24% above its 20-day simple moving average (SMA20), while that difference is up 32.19% for SMA50 and it goes to -35.79% lower than SMA200.
Larimar Therapeutics Inc (NASDAQ: LRMR) currently have 64.03M outstanding shares and institutions hold larger chunk of about 57.92% of that.
The stock has a current market capitalization of $186.32M and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$1.49 in the same period. It has Quick Ratio of 7.48 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LRMR, volatility over the week remained 6.94% while standing at 5.77% over the month.
Stock’s fiscal year EPS is expected to drop by -46.00% while it is estimated to decrease by -2.23% in next year. EPS is likely to shrink at an annualized rate of -7.85% for next 5-years, compared to annual growth of 50.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on January 29, 2025 offering a Buy rating for the stock and assigned a target price of $18 to it. Coverage by Oppenheimer stated Larimar Therapeutics Inc (LRMR) stock as an Outperform in their note to investors on October 16, 2024, suggesting a price target of $26 for the stock. On October 03, 2024, Wedbush Initiated their recommendations, while on October 02, 2024, H.C. Wainwright Initiated their ratings for the stock with a price target of $15. Stock get an Outperform rating from Robert W. Baird on September 04, 2024.
